Want to Win the Next Pitch? Stop Leading With AI.

Why the smartest vendors in life sciences are about to stop saying “AI” — and what they’ll say instead

Read that title again and you might think this is an argument against AI. It is the opposite. AI belongs in almost everything you do. It just does not belong in your headline. The vendors who win the next pitch will be fluent in AI and quiet about it — because by now, the word itself tells a client nothing. AI is the how, not the headline.

And there is a pattern here we have lived through before.

There was a time when they would have. In the late 1990s, “we have a website” won meetings. A decade before that, a fax number signaled you were serious. Go back far enough and “electrically powered” was a genuine selling point — there are old advertisements that bragged about it. Today nobody advertises an electric toaster. The electricity is assumed. It became invisible infrastructure, and the moment it did, it stopped being a reason to choose one company over another.

AI is on exactly that path, and it is moving fast.

The word has lost its edge

Walk a life sciences trade show floor. Read your LinkedIn feed. Sit through three vendor pitches in a row. You will hear the same two words in every booth, every post, every keynote: powered by AI. One analyst flatly called AI “the ultimate corporate buzzword” of the year. The data backs the saturation. Roughly 89% of leading businesses now say they are investing in AI to drive revenue. In pharma specifically, about 75% of companies have made generative AI a strategic priority. Sequoia found that more than 70% of early-stage term sheets in early 2025 asked about AI integration — regardless of industry.

When a capability is in every pitch, it stops being a pitch. It becomes table stakes.

Clients are not tired of AI because they stopped believing in it. They are tired of hearing the word because it has become noise. It tells them nothing about you. If everyone leads with AI, no one is differentiated on AI. You have simply joined a very crowded chorus singing the same note.

Where this is heading is not a guess

This is not the first general-purpose technology to go from miracle to plumbing, and the people building the technology say so out loud.

Andrew Ng has called AI “the new electricity.” Sam Altman, talking to a room of infrastructure investors this year, described a future where “intelligence is a utility, like electricity or water.” Read that the way a vendor should read it. When the person selling the thing tells you it is becoming a utility, he is telling you the differentiation is leaving the thing itself and moving somewhere else.

Utilities do not win on the fact that they exist. They win on what they let you do.

Owning the tool is not the same as getting the result

Here is the number every vendor should sit with.

In 2025, MIT’s NANDA initiative studied 300 AI deployments, interviewed business leaders, and surveyed employees for a report called The GenAI Divide. The finding: about 95% of enterprise generative AI pilots delivered no measurable impact on the P&L. Only 5% created real value. Tens of billions of dollars invested, and nineteen out of twenty efforts produced nothing the CFO could find.

The cause was not the model. As one executive in that research put it: “The hype on LinkedIn says everything has changed. Nothing fundamental has shifted.” The gap was execution — workflow, data, change management, and the simple fact that “deploying a model” and “generating value from a model” are not the same activity, even though the industry keeps treating them as one.

That is the whole argument in one statistic. The tool is necessary. The tool is not the point. The impact is the point, and impact is where almost everyone is failing — which means impact is exactly where a vendor can stand out.

Stop selling AI. Start selling what it does.

The good news is that the commercial impact in life sciences is real, large, and measurable. Marketing and sales is where most of the spend goes, where the buyer feels the most pain, and where AI is already moving the numbers a brand team reports to the board. This is the vocabulary clients actually care about:

Revenue. This is the only number that ends every commercial conversation. AI-driven next best action — the right message, to the right HCP, on the right channel, at the right time — has been tied to sales lifts of roughly 4% to 10% and HCP engagement gains of 30% to 40%. Optichannel approaches have shown a 3x average script lift. Nearly six in ten pharma leaders now report seeing 2x ROI from AI initiatives within a year. A vendor who can credibly connect their work to script lift is no longer pitching a feature. They are pitching a P&L.

Customer experience. The modern HCP is drowning in uncoordinated, irrelevant outreach, and they tune it out. AI that orchestrates engagement around the customer — not the campaign calendar — cuts the noise, reduces message fatigue, and makes the brand feel like a resource rather than a sales pitch. The payoff is the relationship: providers who trust the content engage more, adopt faster, and stay. Satisfaction is not a soft metric here. It is a leading indicator of the script.

Speed and scale of the message itself. This is “do more with less, faster” in its most concrete commercial form. Modular content — pre-approved, reusable building blocks assembled across channels — has cut MLR cycle time by more than half, with some teams taking review from weeks to days and lifting content output tenfold. McKinsey reports that some pharma companies have compressed regulatory submission timelines by 50% to 65% through AI-enabled automation. Faster content velocity is not a back-office nicety. Every month a launch sits stuck in review carries a real opportunity cost in lost market time.

Cost and waste. AI-optimized omnichannel buying has delivered 20% to 30% media budget savings against traditional models. But the sharper story is waste. Promotional material production rose 29% year over year, while an estimated 77% of approved content is rarely or never used by field teams. Read that twice. The industry is spending more to produce more content that no one uses. Generating more assets faster is not the win. Generating the right assets and getting them used is. A vendor who removes that waste is worth more than one who simply adds to the pile.

Notice what is missing from those four paragraphs. The model name. The vendor. The architecture. A brand leader does not buy a script lift because it runs on a transformer. They buy it because it sells more medicine, to more of the right prescribers, at lower cost, with a customer who actually wants to hear from them. Lead with the prescriber and the script. The “how” earns its place only after the “so what” has landed.

And here is the same lesson the MIT data taught us, in commercial clothing. Just as 95% of AI pilots produce no measurable impact, 77% of the content the industry already approves never gets used. More is not the goal. Used, measured, and tied to revenue is the goal. That is the gap a vendor should be selling into — because almost no one is. Fewer than 5% of pharma leaders consider their organization fully mature in using AI for sales and marketing. The differentiation is wide open, and it sits on the impact, not the instrument.

This is the what, so what, now what discipline. The what is the AI capability. The so what is the impact on revenue, experience, speed, and cost. The now what is the commercial strategy it unlocks for that specific brand. Most vendors stop at the what. Stop there and you sound like everyone else.

Impact is the fixed star

Here is the part that should make a vendor exhale.

The quiet anxiety in this market is that the technology moves faster than anyone can absorb. New models every few months. New agent frameworks. A capability you built your pitch around in January is table stakes by June. If your value proposition is the tool, you are on a treadmill that only speeds up. You will always be a little behind, by design.

Anchor on impact and the treadmill stops. Script lift, engagement, speed to market, cost taken out — those goals do not change when the model changes. They are the fixed star. The how underneath can evolve every quarter and your story never breaks, because your story was never about the how. That is what it means to be AI-native: not to wear AI as a badge, but to build it so deeply into how you work that it disappears — the way the strongest companies are internet-native without ever saying so. You become AI-native on the inside so you can stop talking about AI on the outside.

That is the inversion. The vendors who anchor on the capability will spend the next five years exhausted — chasing the frontier, renaming their decks, and re-explaining themselves every quarter. The vendors who anchor on the impact will let the frontier come to them: adopting whatever works, dropping whatever does not, and keeping the same promise to the client the entire time. We will move your number. Become AI-native, then stop talking about it.

The one exception, and even it has a rule

If you are an AI product team — if the model, the agent, or the platform is the thing you sell — then yes, the tool is the conversation. But the rule still holds: lead with what your tool does to a client’s number, then go deep on the unique way you do it. “Our agent resolves 40% of medical inquiries without a human, in a validated and compliant workflow” beats “our agent uses a multi-step reasoning architecture” every time. The mechanism is your proof, not your headline.

For everyone else, your unique use of AI is still worth talking about. It is just not the opening line. It is the evidence you bring after the client believes you can move their business.

Three rules for vendors who want to win the next pitch

First, retire “AI-powered” as a value proposition. It is a feature, not a benefit. Treat it the way you treat “we use computers” — true, necessary, and not worth a slide.

Second, name the impact in the client’s terms. Points of script lift. Points of share. HCP engagement rate. Media dollars saved. Days out of the review cycle. If you cannot tie your AI to a number the client already reports to their board, you have not finished building the pitch.

Third, make the AI invisible and the outcome unmistakable. The goal is for a client to forget they bought “AI” the same way they have forgotten they bought eMail. They will simply notice that the work is faster, the cost is lower, and the strategy is sharper — and they will remember who made that happen.

AI should be the norm, not the shiny object. The vendors who understand that will not be the ones shouting the word the loudest. They will be the ones quiet about the tool and loud about the result.

So — want to win the next pitch? Stop leading with AI. Lead with what it does, and let the technology do its work in the background, where the best infrastructure always has.

Everything else is just noise on the floor.

Evolve your messaging

If your team is still leading with AI, we help you change the story. Kairos Meridian works with the vendors and agencies that serve life sciences to turn an AI-heavy pitch into an impact-led one — sharpening your positioning, tying your capabilities to the numbers a brand team actually reports, and building messaging that holds up as the technology keeps moving.

Kairos Meridian — big-agency thinking, boutique agility. Pharma marketing, data, and AI in service of impact.

Start the conversation today, click here.

---

Sources

SR Analytics, AI in the Pharmaceutical Industry (2026) — 75% of pharma companies made generative AI a strategic priority.

Pharmaphorum, Harnessing AI to Transform End-to-End Customer Engagement (2026) — optichannel 3x average script lift, 80% HCP engagement increase, 20–30% media budget savings; ~6 in 10 leaders seeing 2x AI ROI within a year; fewer than 5% of leaders fully mature in AI for sales/HCP/DTC marketing.

Databricks, Elevating Customer Experience with AI-enabled Omnichannel Next Best Action (2025) — NBA improving HCP engagement 30–40% and increasing sales 4–10%.

TrustRadius, From Buzzword to Backbone (2025) — AI as the year’s defining corporate buzzword.

TTMS, AI in B2B (2025) — 89% of leading businesses investing in AI for revenue growth.

Quickers, citing Sequoia Capital (2025) — 70%+ of early-stage term sheets included AI questions, regardless of industry.

Business Insider and multiple outlets (March 2026) — Sam Altman, “intelligence is a utility, like electricity or water,” BlackRock Infrastructure Summit.

Andrew Ng — “AI is the new electricity” (widely cited).

MIT NANDA, The GenAI Divide: State of AI in Business 2025 — ~95% of enterprise generative AI pilots delivered no measurable P&L impact; only ~5% created significant value.

GetShaman, Modular Content in Pharma — modular content cutting MLR cycle time ~57%; weeks-to-days review and ~10x output (Idorsia case).

Pharmaphorum, Is AI the Missing Link in Fixing MLR (2026), citing McKinsey — 50–65% reduction in regulatory submission timelines; promotional production up 29% YoY; ~77% of approved content rarely or never used by field.